Cardiomyopathy is a heart muscle disease associated with cardiacdysfunction. It is classified according to the structural and func-tional abnormalities of the heart muscle: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive orconstrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), and unclassified cardiomyopathy (Richardson et al., 1996). Ischemic cardiomyopathy is a term frequently used to describe an enlarged heart caused by coronary artery disease, which is usually accompanied by heart failure . Regardless of the category and the cause, cardio- myopathy may lead to severe heart failure, lethal dysrhythmias,and death. Cardiomyopathy causes more than 27,000 deaths each year in the United States (American Heart Association, 2001). The mortality rate is highest for African Americans and the elderly (American Heart Association, 2001).
The pathophysiology of all cardiomyopathies is a series of pro-gressive events that culminate in impaired cardiac output. De-creased stroke volume stimulates the sympathetic nervous system and the renin-angiotensin-aldosterone response, resulting in in-creased systemic vascular resistance and increased sodium and fluid retention, which places an increased workload on the heart. These alterations can lead to heart failure .
DCM is the most common form of cardiomyopathy, with an in-cidence of 5 to 8 cases per 100,000 people per year and increas-ing (Braunwald et al., 2001). DCM occurs more often in men and African Americans, who also experience higher mortality rates (Braunwald et al., 2001). DCM is distinguished by signifi-cant dilation of the ventricles (Fig. 29-8) without significant concomitant hypertrophy (ie, increased muscle wall thickness) and systolic dysfunction. DCM was formerly named congestivecardiomyopathy, but DCM may exist without signs and symp-toms of congestion.
Microscopic examination of the muscle tissue shows dimin-ished contractile elements of the muscle fibers and diffuse necrosis of myocardial cells. The result is poor systolic function. These structural changes decrease the amount of blood ejected from the ventricle with systole, increasing the amount of blood remaining in the ventricle after contraction. Less blood is then able to enter the ventricle during diastole, increasing end-diastolic pressure and eventually increasing pulmonary pressures. Altered valve function can result from the enlarged stretched ventricle, usually resulting in regurgitation. Embolic events caused by ventricular and atrial thrombi as a result of the poor blood flow through the ventricle may also occur. More than 75 conditions and diseases may cause DCM, including pregnancy, heavy alcohol intake, and viral infection (eg, influenza). When the causative factor cannot be identified, the term used is idiopathic DCM. Idiopathic DCM accounts for approximately 25% of all heart failure cases (Braunwald et al., 2001). Early diagnosis and treatment can pre-vent or delay significant symptoms and sudden death from DCM. Echocardiography and ECG are used to diagnose DCM and should be conducted for all first-degree relatives (eg, parents, siblings, children) of patients with DCM (Braunwald et al., 2001).
In HCM, the heart muscle increases in size and mass, especially along the septum (see Fig. 29-8). The increased thickness of the heart muscle reduces the size of the ventricular cavities and causes the ventricles to take a longer time to relax, making it more diffi-cult for the ventricles to fill with blood during the first part of di-astole and making them more dependent on atrial contraction for filling.
The increased septal size may misalign the papillary mus-cles so that the septum and mitral valve obstruct the flow of blood from the left ventricle into the aorta during ventricular contrac-tion. Hence, HCM may be obstructive or nonobstructive. Because of the structural changes, HCM had also been called idiopathic hypertrophic subaortic stenosis (IHSS) or asymmetric septal hyper-trophy (ASH). Structural changes may also result in a smaller than normal ventricular cavity and a higher velocity flow of blood out of the left ventricle into the aorta, which may be de-tected by echocardiography (Braunwald et al., 2001). HCM may cause significant diastolic dysfunction, but systolic function can be normal or high, resulting in a higher than normal ejection fraction.
Because HCM is a genetic disease, family members are ob-served closely for signs and symptoms indicating development of the disease (Fuster et al., 2001). HCM is rare, occurring in men, women, and children (often detected after puberty) (Oakley, 1997) with an estimated prevalence rate of 0.05% to 0.2% (Berul Zevitz, 2002). It may also be idiopathic (ie, no cause can be found).
Restrictive cardiomyopathy (RCM) is characterized by diastolic dysfunction caused by rigid ventricular walls that impair ventric-ular stretch and diastolic filling (see Fig. 29-8). Systolic function is usually normal. Because RCM is the least common cardio-myopathy, representing approximately 5% of pediatric cardiomy-opathies, its pathogenesis is the least understood (Shaddy, 2001). Restrictive cardiomyopathy can be associated with amyloidosis (in which amyloid, a protein substance, is deposited within thecells) and other such infiltrative diseases. However, the cause is unknown in most cases (ie, idiopathic).
ARVC occurs when the myocardium of the right ventricle is pro-gressively infiltrated and replaced by fibrous scar and adipose tis-sue. Initially, only localized areas of the right ventricle are affected, but as the disease progresses, the entire heart is affected. Eventually, the right ventricle dilates and develops poor contractility, right ventricular wall abnormalities, and dysrhythmias. The prevalence of ARVC is unknown because many cases are not recognized. ARVC should be suspected in patients with ventricular tachy-cardia originating in the right ventricle (ie, a left bundle branch block configuration on ECG) or sudden death, especially among previously symptom-free athletes (McRae et al., 2001). The dis-ease may be genetic (ie, autosomal dominant) (Richardson et al., 1996). Family members should be screened for the disease with a 12-lead ECG, Holter monitor, and echocardiography.
Unclassified cardiomyopathies are different from or have char-acteristics of more than one of the previously described cardio-myopathies. Examples of unclassified cardiomyopathies include fibroelastosis, noncompacted myocardium, systolic dysfunc-tion with minimal dilation, and mitochondrial involvement (Richardson et al., 1996).
The patient may have cardiomyopathy but remain stable and without symptoms for many years. As the disease progresses, so do symptoms. Frequently, dilated and restrictive cardiomyopathy are first diagnosed when the patient presents with signs and symp-toms of heart failure (eg, dyspnea on exertion, fatigue). Patients with cardiomyopathy may also report paroxysmal nocturnal dys-pnea, cough (especially with exertion), and orthopnea, which may lead to a misdiagnosis of bronchitis or pneumonia. Other symp-toms include fluid retention, peripheral edema, and nausea, which is caused by poor perfusion of the gastrointestinal system. The pa-tient may experience chest pain, palpitations, dizziness, nausea, and syncope with exertion. However, with HCM, cardiac arrest (ie, sudden cardiac death) may be the initial manifestation in young people, including athletes (Spirito et al., 2000).
Physical examination in the early stage may reveal tachycardia and extra heart sounds. With disease progression, examination also reveals signs and symptoms of heart failure (eg, crackles on pul-monary auscultation, jugular vein distention, pitting edema of dependent body parts, enlarged liver).
Diagnosis is usually made from findings disclosed by the pa-tient history and by ruling out other causes of heart failure, such as myocardial infarction. The echocardiogram is one of the most helpful diagnostic tools because the structure and function of the ventricles can be observed easily. ECG demonstrates dysrhyth-mias and changes consistent with left ventricular hypertrophy. The chest x-ray film reveals heart enlargement and possibly pul-monary congestion. Cardiac catheterization is sometimes used to rule out coronary artery disease as a causative factor. An en-domyocardial biopsy may be performed to analyze myocardial tissue cells.
Medical management is directed toward determining and man-aging possible underlying or precipitating causes; correcting the heart failure with medications, a low-sodium diet, and an exercise-rest regimen ; and controlling dysrhythmias with antiarrhythmic medications and possibly with an implanted elec-tronic device, such as an implantable cardioverter-defibrillator . If patients exhibit signs and symptoms of conges-tion, their fluid intake may be limited to 2 liters each day. The person with HCM may also have to limit physical activity to avoid a life-threatening dysrhythmia. A pacemaker may be implanted to alter the electrical stimulation of the muscle and prevent the forceful hyperdynamic contractions that occur with HCM.
When heart failure progresses and medical treatment is no longer effective, surgical intervention, including heart transplantation, is considered. However, because of the limited number of organ donors, many patients die waiting for transplantation. In some cases, a left ventricular assist device (LVAD) is implanted to sup-port the failing heart until a suitable donor heart becomes avail-able.
When a patient withHCM becomes symptomatic despite medical therapy and a dif-ference in pressure of 50 mm Hg or more exists between the left ventricle and the aorta, surgery is considered. The most common procedure is a myectomy (sometimes referred to as a myotomy-myectomy), in which some of the heart tissue is excised. Septal tissue approximately 1 cm wide and deep is cut from the enlarged septum below the aortic valve. The length of septum removed de-pends on the degree of obstruction caused by the hypertrophied muscle.
Instead of a septal myectomy, the surgeon may open the left ventricular outflow tract to the aortic valve by removing the mi-tral valve, chordae, and papillary muscles. The mitral valve then is replaced with a low-profile disk valve. The space taken up by the mitral valve is substantially reduced by the prosthetic valve compared with the patient’s own valve, chordae, and papillary muscles, allowing blood to move around the enlarged septum to the aortic valve in the area that the mitral valve once occupied. The primary complication of both procedures is dysrhythmia; additional complications are postoperative surgical complications such as pain, ineffective airway clearance, deep vein thrombosis, risk for infection, and delayed surgical recovery.
The first human-to-human heart trans-plant was performed in 1967. Since then, transplant procedures, equipment, and medications have continued to improve. Since 1983, when cyclosporine became available, heart transplantation has become a therapeutic option for patients with end-stage heart disease. Cyclosporine (Neoral, Sandimmune, SangCya) is an immunosuppressant that greatly decreases the body’s rejection of foreign proteins, such as transplanted organs. Unfortunately, cyclosporine also decreases the body’s ability to resist infections, and a satisfactory balance must be achieved between suppressing rejection and avoiding infection.
Cardiomyopathy, ischemic heart disease, valvular disease, rejection of previously transplanted hearts, and congenital heart disease are the most common indications for transplantation (Becker & Petlin, 1999; Rourke et al., 1999). A typical candidatehas severe symptoms uncontrolled by medical therapy, no other surgical options, and a prognosis of less than 12 months to live. A multidisciplinary team screens the candidate before recommend-ing the transplantation procedure. The person’s age, pulmonary status, other chronic health conditions, psychosocial status, fam-ily support, infections, history of other transplantations, compli-ance, and current health status are considered in the screening.
When a donor heart becomes available, a computer generates a list of potential recipients on the basis of ABO blood group compatibility, the sizes of the donor and the potential recipient, and the geographic locations of the donor and potential recipient; distance is a variable because postoperative function depends on the heart being implanted within 6 hours of harvest from the donor. Some patients are candidates for more than one organ transplant: heart-lung, heart-pancreas, heart-kidney, heart-liver.
Orthotopic transplantationis themost common surgical procedure for cardiac transplantation (Fig. 29-9). The recipient’s heart is removed, and the donor heart is implanted at the vena cava and pulmonary veins. Some sur-geons still prefer to remove the recipient’s heart leaving a portion of the recipient’s atria (with the vena cava and pulmonary veins) in place. The donor heart, which usually has been preserved in ice, is prepared for implant by cutting away a small section of the atria that corresponds with the sections of the recipient’s heart that were left in place. The donor heart is implanted by suturing the donor atria to the residual atrial tissue of the recipient’s heart. Both techniques then connect the recipient’s pulmonary artery and aorta to those of the donor heart.
Heterotopic transplantation is less commonly performed(Fig. 29-10). The donor heart is placed to the right and slightly anterior to the recipient’s heart; the recipient’s heart is not removed. Initially, it was thought that the original heart might provide some protection for the patient in the event that the transplanted heart was rejected. Although the protective effect has not been proved, other reasons for retaining the original heart have been identified: a small donor heart or pulmonary hyper-tension (Becker & Petlin, 1999; Kadner et al., 2000).
The transplanted heart has no nerve connections with the re-cipient’s body (ie, denervated heart), and the sympathetic and vagus nerves do not affect the transplanted heart. The resting rate of the transplanted heart is approximately 70 to 90 beats per minute, but it increases gradually if catecholamines are in the cir-culation. Patients must gradually increase and decrease their ex-ercise (ie, extended warm-up and cool-down periods), because 20 to 30 minutes may be required to achieve the desired heart rate. Atropine does not increase the heart rate of these patients.
Heart transplant patients are constantlybalancing the risk of rejection with the risk of infection. They must comply with a complex regimen of diet, medications, ac-tivity, follow-up laboratory studies, biopsies (to diagnose rejection), and clinic visits. Most commonly, patients receive cyclosporine or tacrolimus (FK506, Prograf), azathioprine (Imuran) or myco-phenolate mofetil (CellCept), and corticosteroids (ie, prednisone) to minimize rejection.
In addition to rejection and infection, complications may in-clude accelerated atherosclerosis of the coronary arteries (ie, cardiac allograft vasculopathy [CAV ]or accelerated graft atherosclerosis [AGA]). Although the cause is unknown, the disease is believed to be immunologically mediated (Augustine, 2000; Rourke et al., 1999). Hypertension may be experienced by patients taking cy-closporine or tacrolimus; the cause has not been identified. Osteoporosis frequently occurs as a side effect of the anti-rejection medications and pretransplantation dietary insufficiency and med-ications. Posttransplantation lymphoproliferative disease and can-cer of the skin and lips are the most common malignancies after transplantation, possibly caused by immunosuppression. Weight gain, obesity, diabetes, dyslipidemias (eg, hypercholesterolemia), hypotension, renal failure, and central nervous system, respiratory, and gastrointestinal disturbances may be caused by the cortico-steroids or other immunosuppressants. Other complications are immunosuppressant medication toxicities and responses to the psychosocial stresses imposed by organ transplantation. Patients may experience guilt that someone died for them to live, have anxiety about the new heart, experience depression or fear when rejection is identified, or have difficulty with family role changes before and after transplantation (Augustine, 2000; Becker &Petlin, 1999; Braunwald et al., 2001; Fuster et al., 2001; Rourke et al., 1999).
The 1-year survival rate for patients with transplanted hearts is approximately 80% to 90%; the 5-year survival rate is ap-proximately 60% to 70% (Augustine, 2000; Becker & Petlin, 1999; Braunwald et al., 2001; Fuster et al., 2001; Rourke et al., 1999).
The useof cardiopulmonary bypass for cardiovascular surgery and the possibility of performing heart transplantation for end-stage car-diac disease have increased the need for mechanical assist devices. Patients who cannot be weaned from cardiopulmonary bypass or patients in cardiogenic shock may benefit from a period of me-chanical heart assistance. The most commonly used device is the intra-aortic balloon pump . This pump decreases the work of the heart during contraction but does not perform the actual work of the heart.
More complex devices that actuallyperform some or all of the pumping function for the heart also are being used. These more sophisticated ventricular assist devices (VADs) (Fig. 29-11) can circulate as much blood per minute as the patient’s heart, if not more. Each ventricular assist device is used to support one ventricle. Some ventricular assist devices can be combined with an oxygenator; the combination is called extra-corporeal membrane oxygenation (ECMO). The oxygenator– ventricular assist device combination is used for the patient whose heart cannot pump adequate blood through the lungs or the body.
There are three basic types of devices: centrifugal, pneumatic, and electric or electromagnetic. Centrifugal VADs are external, nonpulsatile, cone-shaped devices with internal mechanisms that spin rapidly, creating a vortex (tornado-like action) that pulls blood from a large vein into the pump and then pushes it back into a large artery. Pneumatic VADs are external or implanted pulsatile devices with a flexible reservoir housed in a rigid exterior. The reservoir usually fills with blood drained from the pa-tient’s atrium or ventricle. The VAD then forces pressurized air into the rigid housing, compressing the reservoir and returning the blood to the patient’s circulation, usually into the aorta. Elec-tric or electromagnetic VADs are similar to the pneumatic VADs, but instead of pressurized air, one or more flat metal plates are pushed against the reservoir to return the blood to the patient’s circulation.
Total artificial heartsare designed to re-place both ventricles. Some require the removal of the patient’s heart to implant the total artificial heart; others do not. All of these devices are experimental. Although there has been some short-term success, the long-term results have been disappointing. Researchers hope to develop a device that can be permanently im-planted and that will eliminate the need for donated human heart transplantation for the treatment of end-stage cardiac disease (Braunwald et al., 2001; Chillcott et al., 1998; Fuster et al., 2001; Rose et al., 1999; Schakenbach, 2001).
Most VADs and total artificial hearts are temporary treat-ments while the patient’s own heart recovers or until a donor heart becomes available for transplantation (ie, “bridge to trans-plant”). Some devices are being investigated for permanent use. Bleeding disorders, hemorrhage, thrombus, emboli, hemolysis, infection, renal failure, right heart failure, multisystem failure, and mechanical failure are some of the complications of VADs and total artificial hearts (Braunwald et al., 2001; Duke & Perna, 1999; Schakenbach, 2001; Scherr et al., 1999). The nursing care for these patients focuses on assessing for and minimizing these complications and involves providing emotional support and education about the mechanical assist device.
Copyright © 2018-2020 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.